Use of Evolocumab in Familial Hyperlipidemia With Isolated Heart Transplant
We describe a novel use of evolocumab for successful postoperative lipid control in a patient with familial hyperlipidemia who underwent isolated heart transplantation. We believe that this case carries valuable lessons regarding post-transplant proprotein convertase subtilisin kexin 9 inhibitor use with implications for the future of combined organ allocation and transplantation waitlist times.
Authors
- Kevin Shah (ORCID: https://orcid.org/0000-0002-3012-9943)
- Colin Mackenzie (ORCID: https://orcid.org/0009-0003-5092-683X)
- McHale Anderson (ORCID: https://orcid.org/0000-0003-1363-7150)
Institutions
- University of Utah (US)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.jaccas.2024.102426
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.57